Stalevo (Carbidopa/Entacapone/Entacapone)

Stalevo (Carbidopa/Levodopa/Entacapone): Patient-Friendly Medicine Guide

Basic Product Information

• International Non-Proprietary Name (INN): Carbidopa, Levodopa, and Entacapone
• Australian Brand Name: Stalevo
• ATC Code: N04BA03 (Levodopa, in combination with decarboxylase inhibitor and COMT inhibitor)
• Available Forms & Strengths:
  • Film-coated tablets in strengths combining:
    • Levodopa: 50mg, 75mg, 100mg, 125mg, 150mg, 200mg, 250mg
    • Carbidopa: 12.5mg, 18.75mg, 25mg, 31.25mg, 37.5mg, 50mg, 62.5mg
    • Entacapone: always 200mg per tablet
• Manufacturers: Novartis Pharmaceuticals Australia Pty Ltd; Sandoz Pty Ltd (generic)
• Prescription Status: Prescription Only Medicine (Schedule 4, S4)

Mechanism of Action

• For Patients: Stalevo helps control the symptoms of Parkinson’s disease by restoring levels of dopamine in the brain. Levodopa is transformed into dopamine, the chemical involved in controlling movement. Carbidopa helps more levodopa reach the brain, and entacapone keeps levodopa working longer so the benefits last throughout the day.
• For Healthcare Professionals: Levodopa is a dopamine precursor converted via DOPA decarboxylase in the brain. Carbidopa is a peripheral DOPA decarboxylase inhibitor, which minimises levodopa metabolism outside the CNS, raising CNS bioavailability and reducing levodopa-induced side effects. Entacapone is a selective and reversible catechol-O-methyltransferase (COMT) inhibitor, reducing peripheral levodopa degradation and extending its half-life and CNS duration of action. The triple therapy reduces motor fluctuations and “off” episodes in advanced Parkinson’s disease.

Pharmacokinetics

• Absorption: Levodopa, carbidopa, and entacapone are well absorbed from the small intestine. Peak plasma levels are usually reached 1–2 hours after taking Stalevo.
• Metabolism: Levodopa is mainly metabolised by decarboxylation and COMT in the periphery and CNS. Carbidopa acts mainly peripherally and is metabolised in the liver. Entacapone is mostly metabolised via glucuronidation in the liver.
• Elimination: Both carbidopa and entacapone are largely excreted via urine as metabolites. Levodopa’s metabolites are passed mainly in urine.
• Duration of action: With entacapone, levodopa’s effect duration is extended on average by 20–30%. Total daily dose may be reduced compared to standard levodopa/carbidopa therapy.

Use in Everyday Life and Best Practices

• Stalevo is used to manage symptoms such as tremor, stiffness, and slowness of movement in people with Parkinson’s disease who experience fluctuations in response to standard levodopa treatment.
• The tablet should be swallowed whole with a glass of water and should not be split or crushed due to the special tablet coating.
• Dosing is tailored to each patient’s symptom-control needs. Always follow your doctor’s instructions.
• Typical starting dose: matched to the patient’s previous total daily levodopa amount, divided across similar dosing intervals (usually 3-6 times daily).
• Tablets are taken at roughly the same times each day to maintain smooth symptom control.
• Avoid sudden discontinuation - withdrawal can result in a serious condition called neuroleptic malignant syndrome (NMS) or sudden worsening of symptoms.
• Keep medication in its original packaging and store below 30°C, away from direct sunlight or moisture.

Dosing: Morning vs Evening

• Morning doses help control movement symptoms after sleep “off” periods, enabling better mobility and daily activity.
• Later or evening doses may help prevent night-time or early-morning off periods, but can sometimes cause insomnia or vivid dreams in some people.
• For best results, take tablets at regular intervals as recommended by your prescriber—consistency is key to stable symptom control.
• Dosage timing may be adjusted for people experiencing “wearing-off” between doses, or if late-day doses affect sleep.
• If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. Do not double up doses.

Taking with Food or on an Empty Stomach

• Stalevo may be taken with or without food. Taking with food may reduce nausea, especially when starting treatment.
• High-protein meals (red meat, cheese, yoghurt, nuts, eggs) can slow or reduce levodopa absorption, potentially reducing its effectiveness.
• To maximise benefit, many patients find it best to take Stalevo 30–60 minutes before or after meals, particularly if eating a protein-rich meal.
• The classic English/Australian diet may be high in protein at dinner; some people adjust main protein intake to lunch or evening if instructed by their doctor.
• Consult your healthcare provider regarding diet adjustments for best outcomes.

Interaction Warnings

Indications

• Official (approved):
  • Treatment of Parkinson’s disease and Parkinsonian syndromes with “end-of-dose” motor fluctuations not adequately controlled on existing levodopa/dopa decarboxylase inhibitor therapy.
• Off-label:
  • Adjunct in advanced Parkinson’s disease with “wearing-off” phenomena

Safety Profile and Side Effects

• Common: Nausea, diarrhoea, dizziness, hallucinations, insomnia, sudden sleep episodes, muscle cramps, “orange” urine discolouration
• Occasional: Constipation, dry mouth, confusion, low blood pressure on standing, sweating, headache, changes in appetite or weight
• Serious/Rare: Severe allergic reaction, uncontrollable movements (dyskinesias), psychosis, liver dysfunction, impulse control disorders (gambling, hypersexuality, compulsive shopping), sudden sleep attacks, serotonin syndrome (when combined with select medications)
• If any serious or concerning side effects occur (such as confusion, hallucinations, chest pain, severe diarrhoea, or allergic reactions), seek medical attention immediately.
• Driving and operating machinery: Stalevo may cause drowsiness, sudden sleep episodes, or dizziness. Do not drive until you know how it affects you.

Guidelines for Proper Use in Australia

• Always follow the dosing and timing instructions provided by your GP or neurologist.
• Attend regular medical reviews to adjust medication and monitor for potential complications.
• Pharmacy dispensing in Australia requires a valid doctor’s prescription. National PBS (Pharmaceutical Benefits Scheme) provides reimbursement for eligible patients with Parkinson’s disease.
• Inform your pharmacist and healthcare team before starting any new medications, supplements, or making significant dietary changes.
• Report all side effects, even minor ones, to your doctor or pharmacist.
• Carry a Stalevo alert card if you are travelling, especially interstate or overseas.
• Medication reviews are recommended annually, or sooner if you notice new or worsening symptoms.

Alternative Treatment Options

• Madopar (Levodopa/Benserazide): Alternative oral levodopa formulation; some patients may tolerate one better than the other.
• Sinemet (Levodopa/Carbidopa): Standard combination therapy, without entacapone. Often initial choice in early Parkinson’s.
• Comtan (Entacapone): May be added to Sinemet/Madopar as a separate tablet, rather than a combination.
• Other options: Dopamine agonists (e.g. pramipexole, ropinirole), MAO-B inhibitors (e.g. rasagiline), amantadine, apomorphine injections or pump, and deep brain stimulation.

Legal, Registration, and Reimbursement Status in Australia

• Stalevo is a registered prescription medicine (AUST R) approved by the TGA (Therapeutic Goods Administration, Department of Health and Aged Care).
• Schedule 4 (Prescription Only Medicine) under the Poisons Standard.
• Funded under the Pharmaceutical Benefits Scheme (PBS) for eligible Parkinson’s patients with motor fluctuations.
• Pharmacy dispensing only by registered Australian pharmacists upon valid prescription.
• Legal status is the same across all Australian states and territories.

Latest Research and Clinical Guidance (2022–2025)

• Recent expert guidelines (Australian Parkinson’s Disease Guidelines, MDS 2022–2024) emphasise optimising individualised therapy and recognise Stalevo as an effective tool for reducing “off” times and simplifying medication regimens.
• 2023 meta-analysis (J Neural Transm. 2023;130(1):1-17) affirms the benefits of triple therapy for motor fluctuation management, with close monitoring for impulse control and psychiatric symptoms.
• Recent studies support the early use of COMT inhibitors to delay disabling “wearing-off” and reduce total daily pill burden.
• Current advice stresses shared decision-making with patients and their families, regular medication review, and improvement of quality of life as central goals.
• Psychiatric safety precautions and routine liver monitoring have been reinforced in recent guidelines.

Availability and Delivery in Australia

• † Final patient price varies with PBS eligibility, dispensing pharmacy, and script specifics.
• * Lower prices apply for PBS-eligible patients.
• All major cities (Sydney, Melbourne, Brisbane, Perth, Adelaide) offer same-day or express courier pharmacy delivery. Rural/regional patients should enquire regarding delivery options.

Frequently Asked Questions (FAQ)

• Q: How quickly will Stalevo start working?
  A: Many people begin to notice a difference in their symptoms within a few days. Full benefits may take 1–2 weeks as dose is adjusted.
• Q: Can I take Stalevo with other medications?
  A: Stalevo may interact with several medicines. Always inform your pharmacist or doctor about all medications, vitamins, or supplements you are taking.
• Q: Is Stalevo suitable for vegetarians or people with allergies?
  A: Stalevo tablets do not contain gluten or animal-derived excipients, but always check the package leaflet or consult the pharmacist for the most current formulation details.
• Q: What if I forget to take a dose?
  A: Take it as soon as you remember unless it’s close to your next scheduled dose. Do not take two doses at once.
• Q: Can I stop Stalevo suddenly?
  A: No. Stopping suddenly can be dangerous and lead to serious symptoms, including a rare but serious reaction called neuroleptic malignant syndrome. Speak to your doctor before making any changes.